#4-62E. Mastering Steroid Tapering: Bridging Therapy Success in Early Rheumatoid Arthritis (ARD, 2026)

Do you often struggle with the optimal timing for steroid withdrawal in early rheumatoid arthritis to minimize adverse effects while maintaining strict disease control? This pivotal study evaluated the success rate of discontinuing prednisolone after a short-term bridging therapy administered alongside initial methotrexate treatment in newly diagnosed rheumatoid arthritis patients. The most crucial finding demonstrates that 84% of patients successfully discontinued prednisolone after following a rigorous 7-week tapering protocol, with an exceptionally low rate of restarting the medication, thereby significantly reducing cumulative glucocorticoid exposure. However, when critically appraising this research, it is important to note a key limitation: the lack of a randomized control group receiving no bridging therapy or an alternative tapering regimen for direct comparison. Despite this, for listening physicians, these findings are highly relevant. They provide robust clinical evidence supporting that the short-term bridging strategy recommended by EULAR is practically achievable, offering a structured approach to rapidly suppress joint inflammation while successfully mitigating the risks of long-term steroid toxicity in daily clinical practice.

Citation: Brinkmann, G. H., et al. Successful discontinuation of oral glucocorticoids after short-term bridging therapy in patients with newly diagnosed rheumatoid arthritis. Annals of the Rheumatic Diseases. 2026. DOI: 10.1016/j.ard.2026.01.003

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.